49. Systemic lupus erythematosus Clinical trials / Disease details
Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCTs071180052 | 26/12/2014 | 15/03/2019 | Control of steroid-associated osteonecrosis of the femoral head in SLE patients | Clinical trial for the control of osteonecrosis of the femoral head secondary to the initial corticosteroid treatment in patients with systemic lupus erythematosus - None | systemic lupus erythematosus;D008180 | Objectives take three below candidate drugs for the prevention for at least 3 months after the initial corticosteroid treatment. 1. Clopidogrel Bisulfate (Plavix) Taking a dose of 300mg once daily on the first day, and a dose of 75mg once daily on subsequent days. 2. Pitavastatin Calcium (LIVALO) Taking a dose of 2mg once daily. 3. Tocopherol Acetate (Juvela) Taking a dose of 100mg three times daily (total of 300mg daily). | Nakashima Yasuharu | NULL | Recruiting | >= 20age old | Not applicable | Both | 150 | Phase 2 | Japan |